By focusing on genetic variations within a primary tumor, differences between the primary and a metastatic tumor, and additional diversity from tumor DNA in the blood stream, physicians can make better treatment choices for patients with gastric and esophageal adenocarcinoma. This study challenges current guidelines and supports evaluation of metastatic lesions and circulating tumor DNA. – Source